NeuroSearch announces revised financial calendar for 2009 and the company's financial calendar for 2010

Copenhagen, 19 October 2009 - NeuroSearch (NEUR) informs that the date for the
announcement of the company's third quarter 2009 report has been changed from
11 November to 16 November 2009: 


Financial calendar for 2009
16 November 2009	Third quarter 2009 report 


For 2010, NeuroSearch's financial calendar is as follows:

Financial calendar for 2010
10 March 2010	Annual Report 2009
28 April 2010	Annual General Meeting and first quarter 2010 report
25 August 2010	Second quarter 2010 report
17 November 2010	Third quarter 2010 report


Flemming Pedersen
CEO



Contact persons:
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118 
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103 


About NeuroSearch  
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug
pipeline comprises eight clinical (Phase I-III) development programmes:
Huntexil™ (pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK.
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates
and holds equity interests in several biotech companies.